Article in Toxins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Kassyo L S DantasLaboratory of Pain, Inflammation, Neuropathy, and Cancer, Department of Immunology, Parasitology and General Pathology, Londrina State University, Londrina 86057-970, PR, Brazil.
Beatriz H S BianchiniLaboratory of Pain, Inflammation, Neuropathy, and Cancer, Department of Immunology, Parasitology and General Pathology, Londrina State University, Londrina 86057-970, PR, Brazil.
Matheus D V da SilvaLaboratory of Pain, Inflammation, Neuropathy, and Cancer, Department of Immunology, Parasitology and General Pathology, Londrina State University, Londrina 86057-970, PR, Brazil.ORCID 0000-0001-7414-7919
Maiara PivaLaboratory of Pain, Inflammation, Neuropathy, and Cancer, Department of Immunology, Parasitology and General Pathology, Londrina State University, Londrina 86057-970, PR, Brazil.ORCID 0000-0003-4099-3492
Joice M da CunhaDepartment of Pharmacology, Federal University of Paraná, Curitiba 81531-980, PR, Brazil.ORCID 0000-0003-0897-091X
Janaina M ZanoveliDepartment of Pharmacology, Federal University of Paraná, Curitiba 81531-980, PR, Brazil.ORCID 0000-0002-3448-5646
Fernanda C CardosoInstitute of Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.ORCID 0000-0002-0068-9974
Fabiana T M C VicentiniSchool of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto 14040-903, SP, Brazil.ORCID 0000-0002-0842-9130
Camila R FerrazLaboratory of Pain, Inflammation, Neuropathy, and Cancer, Department of Immunology, Parasitology and General Pathology, Londrina State University, Londrina 86057-970, PR, Brazil.ORCID 0000-0003-4550-0773
Patricia B ClissaLaboratory of Immunopathology, Butantan Institute, São Paulo 05503-900, SP, Brazil.
Rubia CasagrandeDepartment of Pharmaceutical Sciences, Center of Health Sciences, Londrina State University, Londrina 86039-440, PR, Brazil.ORCID 0000-0002-2296-1668
Waldiceu A VerriLaboratory of Pain, Inflammation, Neuropathy, and Cancer, Department of Immunology, Parasitology and General Pathology, Londrina State University, Londrina 86057-970, PR, Brazil.ORCID 0000-0003-2756-9283
Funding
CAPES finance code 001CNPq #309633/2021-4, #405027/2021-4, #307852/2019-9; #481049/2012-6; #427946/2018-2 and # 405848/2025-0Fundação Araucária PROPPG 06/2025 - Internacionalize 2025; PRONEX grant agreement 014/2017, protocol 46.843 and grant call PROPPG-PBA #067/2024Governo do Estado do Paraná, Conselho Paranaense de Ciência e Tecnologia, e Secretaria de Es-tado da Ciência, Tecnologia, e Ensino Superior (SETI) dotação orçamentária #4560.19.571.06.6153; eprotocolo 21.234.745-0
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Maresin 2, a Specialized Pro-Resolution Lipid Mediator, Reduces Pain and Inflammation Induced by · full record | OpenQuestion